Media coverage of PrEPVacc's July 2024 vaccine result announcement
Following the announcement by PrEPVacc investigators that the HIV vaccines tested in PrEPVacc fail to reduce infections, media outlets covered the news, including the following:
Tuesday 23 July
Correio Braziliense: HIV/Aids: Menos pessoas têm a doença, mas mundo está longe da meta
The Citizen (Tanzania): HIV vaccine flops in trials
Mwananchi (Tanzania) - Majaribio chanjo kuzuia VVU yakosa ufanisi
The Microbiologist: HIV vaccines tested in PrEPVacc fail to reduce infections
Forbes.com - Despite Gilead’s Promising HIV Prevention Drug, A Vaccine Is Still The ‘Holy Grail’
Monitor (Uganda) - HIV vaccine trial: Experts explain ‘false positive’ tests
Wednesday 24 July
News24: Placebo outperformed HIV vaccine tested in SA, Uganda, Tanzania, study results show
ScienceBlog: HIV Vaccine Trial Fails to Prevent Infections, Raises New Questions
The Heritage Times: Africa’s HIV Vaccine Trial Suspended Following Unfavorable Initial Outcomes
Le Quotidien du Medecin: Traitement et prévention du VIH : du nouveau sur le PrEPVacc, le cabotégravir et l’abacavir au congrès AIDS 2024
la Repubblica: HIV, fallito il test dei vaccini PrEPVacc
Apotheke Adhoc: Aids: HIV-Impfstofftest gescheitert
Friday 26 July
263chat.com (Zimbabwe): PrEPVacc Study Fails to Demonstrate Efficacy of HIV Experimental Vaccines
Friday 2 August
Precision Vaccinations: HIV Vaccine Candidates Fail to Reduce Infections